Based on these results, a clinical trial (NCT#04074746) is underway in patients with relapsed/refractory CD30+ lymphomas using cytokine-pre-activated and feeder cell-expanded cord-blood NK cells that were complexed with AFM13 [48]. The gene discussed is TNFRSF8; the disease is lymphoma.